Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$9.15 USD
-0.41 (-4.29%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $9.21 +0.06 (0.66%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Foghorn Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 234 | 346 | 154 | 186 | 16 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 300 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 6 | 5 | 5 | 1 |
Total Current Assets | 240 | 351 | 460 | 191 | 17 |
Net Property & Equipment | 13 | 15 | 18 | 20 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 4 | 4 | 3 | 2 |
Total Assets | 286 | 405 | 520 | 256 | 22 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 4 |
Accounts Payable | 6 | 5 | 4 | 4 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 11 | 10 | 9 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 35 | 33 | 28 | 2 | 0 |
Total Current Liabilities | 58 | 55 | 49 | 19 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 268 | 304 | 323 | 13 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 20 | 11 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 363 | 405 | 423 | 109 | 24 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 87 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 395 | 377 | 361 | 309 | 6 |
Retained Earnings | -472 | -373 | -264 | -163 | -94 |
Other Equity | -1 | -4 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -77 | 0 | 97 | 146 | -1 |
Total Liabilities & Shareholder's Equity | 286 | 405 | 520 | 256 | 22 |
Total Common Equity | -77 | 0 | 97 | 146 | -88 |
Shares Outstanding | 42.20 | 41.80 | 37.00 | 35.80 | NA |
Book Value Per Share | -1.83 | 0.00 | 2.62 | 4.08 | 0.00 |
Fiscal Year End for Foghorn Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 285 | 207 | 234 | 260 | 284 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 5 | 6 | 6 | 6 |
Total Current Assets | 290 | 212 | 240 | 265 | 290 |
Net Property & Equipment | 11 | 12 | 13 | 14 | 15 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 3 | 3 | 3 | 3 |
Total Assets | 329 | 255 | 286 | 313 | 340 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 6 | 6 | 7 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 6 | 9 | 9 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 31 | 32 | 35 | 28 | 34 |
Total Current Liabilities | 51 | 52 | 58 | 52 | 57 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 260 | 266 | 268 | 280 | 292 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 343 | 352 | 363 | 371 | 389 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 506 | 400 | 395 | 392 | 386 |
Retained Earnings | -520 | -497 | -472 | -447 | -433 |
Other Equity | 0 | -1 | -1 | -2 | -3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -14 | -97 | -77 | -57 | -49 |
Total Liabilities & Shareholder's Equity | 329 | 255 | 286 | 313 | 340 |
Total Common Equity | -14 | -97 | -77 | -57 | -49 |
Shares Outstanding | 55.30 | 42.50 | 42.20 | 41.80 | 41.80 |
Book Value Per Share | -0.26 | -2.29 | -1.83 | -1.37 | -1.18 |